Allogene Therapeutics Inc (ALLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 22 | 30 | -40 | 49 | 86 |
| Gross Profit | 22 | 30 | -40 | 49 | 86 |
| Operating Expenses | 80,562 | 99,122 | 96,421 | 82,538 | 76,680 |
| Operating Income | -80,540 | -99,092 | -96,461 | -82,489 | -76,594 |
| Other Income | 1,308 | -876 | -6,168 | -659 | 1,807 |
| Pre-tax Income | -79,232 | -99,968 | -102,629 | -83,148 | -74,787 |
| Net Income Continuous | -79,232 | -99,968 | -102,629 | -83,148 | -74,787 |
| Net Income | $-79,232 | $-99,968 | $-102,629 | $-83,148 | $-74,787 |
| EPS Basic Total Ops | -0.54 | -0.69 | -0.72 | -0.58 | -0.52 |
| EPS Basic Continuous Ops | -0.54 | -0.69 | -0.71 | -0.58 | -0.52 |
| EPS Diluted Total Ops | -0.54 | -0.69 | -0.72 | -0.58 | -0.52 |
| EPS Diluted Continuous Ops | -0.54 | -0.69 | -0.71 | -0.58 | -0.52 |
| EBITDA(a) | $-77,971 | $-95,077 | $-93,237 | $-78,134 | $-72,011 |